Acurx Pharmaceuticals Inc (ACXP) Actualités

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire STATEN ISLAND...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI) PR Newswire STATEN ISLAND...

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications PR Newswire STATEN ISLAND...

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset PR Newswire STATEN ISLAND, N.Y., Nov. 20, 2024 STATEN ISLAND, N.Y., Nov. 20...

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y., Nov. 13, 2024 STATEN...

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific...

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level...

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 PR Newswire STATEN ISLAND, N.Y., Oct. 16, 2024 STATEN...

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues PR...

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier...